Posted by Blue Matter on November 8th, 2019.
The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team. These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues.
The third Breakfast Club meeting was on 5th November 2019 at Skylounge restaurant in Zug, Switzerland. The guest speaker was Theresa Heggie, Senior Vice President and Head of CEMEA for Alnylam Pharmaceuticals.
The title of the presentation and discussion was, Building a World-Class Biotech Business in Europe and Beyond: Transitioning from R&D to Commercial and US to International. Key topics were:
- Alnylam’s Journey: A brief overview of the key phases Alnylam ventured through on its journey from its founding to today
- Alnylam Today: A look at Alnylam’s current situation as a world leader in RNAi therapeutics
- Five Top Tips: Key things learned as Alnylam developed and commercialized a successful product and transitioned from a purely R&D-focused company to one with robust R&D and commercial capabilities, as well as from a US-focused company to an international organization
Here, you can access an outline-based summary of the discussion: